Purpose of Review Chlorhexidine gluconate (CHG) and mupirocin are increasingly used for Staphylococcus aureus decolonization to prevent healthcare-associated infections; however, increased use of these agents has led to concerns for growing resistance and reduced efficacy. In this review, we describe current understanding of reduced susceptibility to CHG and mupirocin in S. aureus and their potential clinical implications. Recent Findings While emergence of S. aureus tolerant or resistant to topical antimicrobial agents used for decolonization is well described, the clinical impact of reduced susceptibility is not clear. Important challenges are that standardized methods of resistance testing and interpretation are not established, and the risk for selection for co-or cross-resistance using universal, as opposed to targeted decolonization, is unclear. Summary Evidence continues to support S. aureus decolonization in certain patient groups, although further studies are needed to determine the long-term impact of CHG and mupirocin resistance on efficacy. Strategies to mitigate further development of reduced susceptibility and the consequences of selection pressures through universal decolonization on resistance will benefit from further investigation.
Introduction
Staphylococcus aureus colonization of the nares occurs in approximately 20-40% of patients [1] [2] [3] and imparts a three-to sixfold increased risk of healthcare-associated infection (HAI) due to S. aureus [2] , leading to increased length of stay and cost compared to non-colonized patients [4] . Most HAIs caused by S. aureus are due to strains carried by patients before they developed infection [5] . Consequently, over the last several decades, clinicians have sought to reduce S. aureus HAIs by eliminating S. aureus carriage. Interest in decolonization grew further as the prevalence of methicillin-resistant S. aureus (MRSA) dramatically rose in hospitals and then communities around the world. Patients who carry MRSA are fourfold more likely to have MRSA infection (compared to patients colonized with methicillin-sensitive S. aureus (MSSA)) [6] , suffer 30% higher 30-day mortality [7] , and serve as a reservoir for transmission to other patients and the community.
Decolonization refers to the elimination of carriage or reduction of the microbial burden of one or more pathogens from the body through the use of biocidal agents [8] . Decolonization strategies may be targeted to colonized patients or given universally to all patients. Topical chlorhexidine gluconate (CHG) (given as a bath or using impregnated wipes) and/or topical mupirocin ointment (typically 2% concentration, administered intranasally two to three times daily for 5-7 days) for S. aureus decolonization have been shown to reduce HAIs and are widely utilized in multiple healthcare settings. CHG is used for additional healthcare applications including hand hygiene, periprocedural disinfection, and for the prevention of central line-associated bloodstream infections (CLABSI) infections through impregnated dressings.
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Topical agents have many advantages over systemic agents. For example, they limit systemic exposure while achieving high concentrations at the site of bacteria. Furthermore, the biocidal activity of CHG persists long after application compared to other antiseptics [9] . However, with increased use, reduced bacterial susceptibility to these compounds has emerged. Whether this reduced susceptibility is clinically meaningful is not certain but may depend on the agent, the degree of nonsusceptibility, and the application.
In this review, we summarize the emergence of S. aureus resistance to CHG and mupirocin in the context of their use for decolonization. We then focus on potential implications and evidence for reduced efficacy, consider the potential clinical implications of universal decolonization strategies on resistance, and conclude by posing questions and research that may guide thoughtful use and potential alternatives to CHG and mupirocin for the prevention of S. aureus-related healthcare-associated infections in the future. CHG and mupirocin are studied and employed most extensively in the context of S. aureus decolonization; thus, the scope of this review will be S. aureus resistance with only a limited discussion of non-staphylococcal resistance.
The Importance of Mupirocin and Chlorhexidine Gluconate for Decolonization and Prevention of HAIs
An estimated 720,000 HAIs occur each year in US hospitals, for which S. aureus is the second leading causative pathogen (behind Clostridium difficile) and the most common identifiable cause of healthcare-associated surgical site infections [10] . HAIs due to MRSA are associated with two to three times the risk of 30-day mortality compared to patients without MRSA infection [7] .
Level 1 evidence supports S. aureus decolonization in ICU patients to reduce MRSA colonization and bloodstream infections [11, 12•, 13, 14] . Evidence-based guidelines also recommend S. aureus decolonization of perioperative surgical patients for prevention of surgical site infections [15, 16] , especially cardiothoracic and orthopedic surgeries [17] . The benefits of S. aureus decolonization in other non-ICU, nonsurgical inpatient settings outside of certain high-risk patient populations (e.g., hemodialysis [18] or with central venous catheters [19] ), remain to be determined [20] .
Review of Chlorhexidine Gluconate Resistance and Influencing Factors
Developed in the 1950s, CHG is an antiseptic with broad biocidal activity including gram-positive and gramnegative bacteria, fungi, and enveloped viruses [21] . The bactericidal mechanism of CHG is thought to act through binding the cell wall, leading to osmotic disruption and cell death (Fig. 1) [22] . CHG is the water soluble form of a divalent cationic biguanide [23] and is generally regarded as safe and well tolerated when applied topically (typical concentrations ranging from 0.5 to 4%) [22] , although rare allergic reactions have been reported [24] . With this strong safety and tolerability record, CHG is a mainstay antiseptic used in a wide range of healthcare products, including oral care rinses, hand hygiene rubs, soaps, CHG-impregnated catheter dressings, and CHG-impregnated catheters [25••, 26-28] . CHG-alcohol prepping solution is the preferred agent for skin antisepsis prior to central venous catheter placement or surgery [29] .
S. aureus resistance to CHG is thought to occur primarily through efflux pumps [30•] encoded by quaternary ammonium compound (qac) genes, particularly qacA and qacB [31] ; however, their exact role in CHG resistance is not well understood. Although the lack of a standard definition for CHG susceptibility prevents comparability of data in many cases, studies using internally valid methodologies suggest CHG resistance increases over time with widespread use [32, 33•] . A summary of the definitions, mechanisms, and prevalence of S. aureus CHG resistance is in Table 1 .
Limitations to Defining CHG Resistance
Phenotypic CHG resistance is most commonly defined as a minimum inhibitory concentration (MIC) ≥ 4 μg/mL by broth dilution; however, this definition is not standardized and may not be clinically relevant [38] . The use of MIC to determine CHG resistance has been questioned for several reasons. First, the inhibitory effects are less important than the bactericidal effects of an antiseptic, such as CHG. Second, broth dilution does not take into account the significant residual biocidal activity of CHG over time [9] . Third, CHG concentrations attained topically are orders of magnitude higher than those considered to represent CHG resistance. For example, a 0.5% CHG aqueous solution equates to roughly 5,000 μg/mL [38] . It has been noted that the term "resistance" may be an inaccurate term for biocides like CHG [38] . While some microbes, like spores, are intrinsically non-susceptible to CHG [25••] , others can survive at least lower concentrations of CHG (e.g., 4 μg/ mL), due to persistence in the protective environment of a biofilm ("phenotypic tolerance") [41] or through overexpression of efflux pumps ("chlorhexidine tolerance") [42, 49] . Consequently, some prefer the term "reduced susceptibility" [38] or "tolerance" [39] rather than resistance. For purposes of simplicity and consistency, we will refer to CHG resistance in this review.
The presence of qacA/B is often used as a marker or surrogate for phenotypic CHG resistance; however, the relationship between genotypic and phenotypic resistance is inconsistent. These discrepancies may be due to the inability of qacB (which is genetically difficult to distinguish from qacA without sequence analysis) to interact with CHG as a substrate or the presence of other multidrug efflux pumps active against CHG [34••] .
Review of Mupirocin Resistance and Influencing Factors
Mupirocin, previously known as pseudomonic acid A, is a naturally occurring antibiotic produced by the soil bacterium Pseudomonas fluorescens that inhibits bacterial isoleucyl t-RNA synthetase ( Fig. 1) [50] . The spectrum of clinically useful antibacterial activity of mupirocin includes broad gram- Phenotypic: Measurement of bacterial susceptibility to CHG is problematic, and no standard methods for susceptibility testing exist; however, isolates with CHG MIC ≥ 4 μg/mL are generally recognized as resistant [34••] . Note. CHG diffuses poorly in agar and thus broth dilution method is preferred over disk diffusion [35] . Genotypic: As qacA/B-positive isolates typically have a CHG MIC ≥ 8 μg/mL [36] , the presence of qacA/B has been used as a marker for CHG resistance [37] . However, S. aureus strains carrying qacA/B have been reported as CHG susceptible [32] and vice versa [38, 39] .
Intrinsic resistance: Intrinsic CHG tolerance may be seen with non-enveloped viruses, certain non-fermenting gram-negative bacteria (e.g. Pseudomonas spp.), and mycobacteria [40] . Bacterial spores [25••] and biofilm formation [41] are also associated with reduced CHG effectiveness. Acquired resistance: qacA/B carriage is highly variable in different settings. The presence of qacA/B in staphylococci does not invariably confer phenotypic CHG resistance [42] , and other qac genes (e.g., smr, cepA, qacE) [43] have also been associated with CHG resistance.
Prevalence of CHG resistance among S. aureus isolates ranges widely among healthcare settings, with increasing prevalence associated with higher levels of CHG use and clinical (versus surveillance) isolates, from 0.6% [34••] of the inpatient surveillance isolates, 0.9-1.6% [44, 45] of the outpatient surveillance or clinical isolates, 17-33% [36, 46] of the ICU surveillance isolates, and up to 70% [47] of the clinical isolates (from Iranian hospitals with extensive CHG use). The prevalence of qacA/B-positive MRSA isolates has dramatically risen between 1990 and 2012 [48] .
CHG chlorhexidine gluconate, MIC minimal inhibitory concentration, qacA/B quaternary ammonium compound genes A and B, MRSA methicillinresistant Staphylococcus aureus positive coverage, including methicillin-resistant S. aureus (MRSA). Mupirocin is rapidly metabolized and rendered inactive in the body, limiting its clinical use to topical applications, primarily nasal decolonization of S. aureus and impetigo. Low levels of mupirocin in the environment are thought to generate a state of amino acid starvation, thereby increasing mutation rates and promoting acquisition of resistance that can spread either through clonal transmission or plasmid-mediated horizontal transfer from other bacteria, such as coagulasenegative staphylococci (CoNS).
The development of mupirocin resistance associated with widespread use of the antibiotic is well documented [51] . For example, one hospital observed the prevalence of mupirocin resistance among MRSA isolates rise from 2.7% at baseline to 65% 18 months after implementation of a universal mupirocin-based decolonization protocol [52] . Conversely, a Brazilian hospital saw the prevalence of high-level mupirocin resistance among MRSA clinical isolates fall from 44 to just 6% after instituting a policy restricting mupirocin use (from unrestricted use in all patients with MRSA colonization or infection plus treatment of skin infections to use only for targeted decolonization) [53] . The use of mupirocin to treat skin and soft tissue infections also promotes mupirocin resistance [54] , and its role in treatment of impetigo has been questioned [55] .
Similar to hospitals, communities with easy mupirocin access (e.g., over-the counter availability) have a high prevalence of mupirocin resistance [56] . At a Veterans Affairs Medical Center, the percentage of high-level mupirocin resistant MRSA isolates decreased from 31% during a period of unrestricted mupirocin use between 1990 and 1993 to 4% after strict "administrative control" of mupirocin prescriptions was implemented in 2000-2001 [57] . In New Zealand, unrestricted mupirocin use was associated with higher rates of resistance (28%) during a period of over-the-counter mupirocin availability from 1991 to 2000 [56] and resistance dropped significantly (to 11%) by 2013 following policy changes to restrict mupirocin use [58] . A summary of the definitions, mechanisms, and prevalence of S. aureus mupirocin resistance is in Table 2 .
Clinical Implications of Reduced Susceptibility to S. aureus Decolonization Agents
While there is convincing evidence to suggest that decolonization strategies to control S. aureus using CHG and mupirocin promote resistance to these agents, the clinical implications of resistance in terms of decolonization failure, reduced efficacy to prevent HAIs, or development of co-or cross-resistance are unclear. For example, Suwantrarat and colleagues analyzed 150 CLABSI-related intensive care unit (ICU) clinical isolates and found 64% overall prevalence of CHG resistance in units without routine CHG bathing, compared to 86% among units with routine CHG bathing [33•] . Although the greatest Mupirocin resistance, particularly high-level resistance, is associated with decolonization failure [44, 69] . However, like CHG, the impact on efficacy in reducing HAIs is not clear in clinical studies. Furthermore, in vitro studies suggest the mupirocin resistance phenotype may come at a fitness cost in the absence of mupirocin [64] .
While isolated CHG resistance is not directly associated with decolonization failure, the combination of qacA/B and lowlevel mupirocin resistance is shown to contribute to MRSA decolonization failure (defined as at least one positive weekly screening or clinical isolate within 1 year after decolonization) [70] . Although the impact of reduced decolonization failure on efficacy to prevent HAIs is unclear, the prevalence of qacA/B genes appear enriched among clinical isolates compared to isolates obtained for surveillance, suggesting a possible link to decolonization or disinfection failure, increased virulence, or antimicrobial co-resistance. For example, qacA/B-carrying S. aureus isolates are associated with invasive bloodstream infections [39] and Cho and colleagues found that ICU patients carrying qacA/B-positive MRSA were more likely have a clinical isolate (rather than just a surveillance MRSA isolate) and longer hospital stays compared to patients carrying qacA/Bnegative MRSA [36] . In addition, non-S. aureus bacteria may develop resistance following exposure to CHG; for example, increased Acinetobacter baumannii and Staphylococcus epidermidis resistance to CHG were observed 1 year following institution of routine CHG bathing [71] .
The development of co-resistance (horizontal transfer of resistance genes affecting susceptibility to other antimicrobials or antiseptics) between mupirocin, CHG, and/or other antimicrobials or antiseptics is a worrisome feature that may be potentiated through selection pressure by their widespread use. Plasmids carrying qacA/B genes have been identified in S. epidermidis, Staphylococcus hominis, Listeria monocytogenes [72] , and carbapenem-resistant Klebsiella pneumoniae [73] . CHG and mupirocin co-resistance are known to occur via the pSK1 family of conjugative staphylococcal multidrugresistance plasmids [74] , which may harbor resistance genes for other antibiotics such as β-lactams [75] and MRSA isolates are often less susceptible to CHG compared to methicillinsensitive S. aureus (MSSA) [76] . Insertion sequences, particularly IS257, flanking the mupA gene may allow recombination to occur with chromosomal DNA [77] .
Similarly troubling are several studies indicating that CHG resistance may promote antibiotic cross-resistance [38] defined as a resistance mechanism leading to resistance to more than one agent. In one in vitro evolution study, repeated exposures of CHG led to reduced susceptibility of vancomycinresistant Enterococcus faecium isolates to daptomycin [78] . While CHG cross-resistance in S. aureus is controversial [30•, 79] , MRSA strains have been associated with CHG [80] and mupirocin [81] resistance. Whether selection for methicillin resistance is caused by or simply associated with resistance these agents is not clear. Aside from antibiotics, efflux-mediated cross-resistance to other antiseptics used for hospital cleaning could theoretically occur; however, to our knowledge, inadequate environmental disinfection has not been associated with CHG resistance for bacteria not already known to be CHG tolerant (e.g., Pseudomonas and Klebsiella spp.) [82] . Given its unique mechanism of action, mupirocin cross-resistance to other clinically used antibiotics is not known to occur [83] .
Universal Versus Targeted Decolonization Strategies
Debate exists whether decolonization strategies should best be implemented universally for all patients, regardless of their colonization status, or targeted to patients with identified S. aureus colonization. Universal decolonization may be less time intensive (without the necessity for screening nasal culture or PCR) and more efficacious but increased CHG and mupirocin exposure risks potentially worsening resistance. The REDUCE-MRSA three-arm, cluster-randomized trial of ICU patients at 43 hospitals compared screening plus isolation without decolonization, targeted decolonization of MRSAcolonized patients with CHG and mupirocin, or universal decolonization with CHG and mupirocin. Studying over 122,000 patients over 30 months, the study showed that universal decolonization was superior to targeted decolonization and screening plus isolation without decolonization in reducing MRSA infections (hazard ratios 0.92, 0.75, and 0.63, respectively) and all-cause bloodstream infections (hazard ratios 0.99, 0.78, and 0.56, respectively) [12•] . A universal decolonization strategy is proposed for prevention of surgical site infections as well [84•] .
While the authors of the REDUCE-MRSA trial argue that universal decolonization may be more cost-effective, a metaanalysis published in 2009 found mupirocin to be cost effective only when a targeted decolonization approach was used [85] . In addition, universal decolonization may theoretically predispose towards the development of S. aureus antimicrobial resistance not only by selection of tolerant S. aureus clones but also through increased horizontal gene transfer from CoNS. In a separate study, in vivo transfer of plasmid-borne mupA between CoNS and MRSA was observed in a patient who developed high-level mupirocin-resistant MRSA during mupirocin treatment, suggesting that CoNS commensals may serve as an environmental reservoir for mupirocin resistance [86] . Consequently, some have advocated to limit mupirocin exposure to S. aureus-colonized patients in order to reduce the risk of emerging resistance [53] . However, a follow-up study of 3,3173 MRSA isolates from the REDUCE-MRSA trial was performed to assess CHG and mupirocin resistance and found only 2 CHG-resistant isolates by broth dilution (defined as MIC ≥ 8 μg/mL), both occurring during periods without CHG/mupirocin decolonization [34••] . High-level mupirocin resistance was more common in the universal decolonization arm compared to the arms without decolonization or targeted decolonization; however, the difference was not statistically significant and the intervention period was short (18 months).
Mathematical models to evaluate the risk of resistance associated with universal decolonization show mixed findings. A model published by Hetem and colleagues (that accounted for ecological factors such as horizontal gene transmission from CoNS to S. aureus) concluded that the likelihood of worsening S. aureus mupirocin resistance through universal decolonization is negligible compared to a targeted decolonization strategy or no decolonization [84•] . However, a different model by Deeny and colleagues suggested that a universal decolonization could lead to a significantly higher prevalence of mupirocin resistance among MRSA strains compared to targeted decolonization after 5 years (21 versus 9% estimated prevalence of mupirocin resistance, respectively) [87•].
Alternative Decolonization Agents
With increasing resistance, alternative agents for decolonization may need to be considered. Investigational antibiotic or antiseptic alternatives for mupirocin-based S. aureus decolonization include neomycin, povidone-iodine, fusidic acid, triclosan, intranasal CHG, lysostaphin, ethanol, and omiganan pentahydrochloride; however, the clinical efficacy of these agents is largely unknown [25••, 61, 88•, 89, 90] . Among these agents, only intranasal povidone-iodine has been directly compared to mupirocin in arthroplasty and spine fusion patients and was equivalent for the prevention of SSIs when either intervention was combined with CHG skin wipes [91] . Relative efficacy of other agents will require head-to-head trials with mupirocin. Non-antibiotic/non-antiseptic alternatives that have been proposed include bacteriophage therapy [92] , probiotics [93] , medical-grade honey [61•, 94] , and tea tree oil [61•] . If efficacious, these products would theoretically have an advantage of achieving decolonization without selecting for antimicrobial resistance.
As an alternative antiseptic to CHG, dilute sodium hypochlorite (bleach) bathing was shown to be superior to CHG (both combined with intranasal mupirocin) for S. aureus eradication in a randomized controlled trial [95] . Octenidine dihydrochloride (combined with mupirocin) has also been investigated as another potential CHG substitute [96] , but a recent prospective crossover trial failed to demonstrate a benefit to octenidine dihydrochloride body washing to prevent MRSA acquisition or MRSA infection [97] .
Systemic antibiotics have been used to enhance topical decolonization and could play a future role in the management of increasing resistance to decolonization agents. Parras and colleagues studied mupirocin versus intranasal fusidic acid plus oral trimethoprim/sulfamethoxazole (both in combination with CHG bathing) and found that they were equally effective for nasal MRSA decolonization [98] . Another study by Simor and colleagues demonstrated that oral antibiotics (rifampin and doxycycline for 7 days), in combination with CHG and mupirocin, successfully decolonized hospitalized MRSAcolonized patients [69] . While the systemic antibiotic approach was not originally intended to combat CHG or mupirocin resistance but rather to address multisite, extranasal MRSA carriage such as gastrointestinal, perineum, or skin [61•] , oral antibiotics may conceivably be used in certain high-risk populations identified as having CHG and/or mupirocin resistant strains in whom the benefits of effective decolonization may outweigh the risks of systemic antibiotic exposure or in whom decolonization protocols using mupirocin and CHG or dilute bleach have failed. However, the routine use of oral antibiotics for S. aureus eradication is not recommended by current IDSA Clinical Practice Guidelines [99] .
Discussion
CHG and mupirocin remain cornerstones for S. aureus decolonization for the prevention of HAIs; however, the emergence of resistance with widespread use raises questions about continued efficacy and implications for infection control. The development of CHG and mupirocin resistance associated with decolonization is poorly characterized and may be underappreciated. However, despite the association between resistance and increased decolonization failure, HAIs due to MRSA have in fact decreased by over 50% between 2005 and 2011 [100] , despite increasing mupirocin and CHG resistance during this time [48, 51, 61•] . Reasons for retained decolonization efficacy may be because in vitro measures of resistance are clinically irrelevant or that trials are inadequately designed to account for the development of resistance over time.
Many studies demonstrating efficacy of decolonization to reduce infections failed to measure mupirocin or CHG susceptibility were performed in a background of low S. aureus resistance, or had a short follow-up period. For example, one of the largest multicenter randomized trials demonstrating the efficacy of perioperative nasal mupirocin/CHG decolonization involving 918 perioperative S. aureus colonized patients (showing a 56% reduced rate of S. aureus infection with decolonization compared to placebo) was performed in a population with a low background rate of S. aureus resistance; all 1,270 S. aureus nasal isolates collected in the study were methicillin and mupirocin susceptible [2] . Mupirocin resistance, which is expected to take several years to develop [87•], may not have had sufficient time to develop during the two year study [2] . Furthermore, CHG resistance was not measured.
Defining resistance is a challenge with no clear consensus definition for CHG or mupirocin resistance. In addition, MIC is an imperfect measure of phenotypic CHG resistance. Alternative CHG susceptibility methods have been proposed and deserve further scrutiny, including surface disinfection and residue testing [79] , time-kill curve [101] , epidemiologic cutoff values [30•, 102] , and mean bactericidal concentration (MBC) [38] . On a molecular level, while the presence of mupA predicts mupirocin phenotypic resistance, the detection of efflux pump genes such as qacA/B likely provides an incomplete picture of CHG resistance. In addition to the difficulty of defining, detecting, and performing surveillance for mupirocin and CHG resistance, it is also unclear how resistance to these agents should influence clinical practice and what role, if any, there is for alternative options for decolonization.
Conclusion
S. aureus colonization is a well-recognized and modifiable risk factor for infections due to S. aureus. Evidence continues to support the use of CHG and mupirocin-based decolonization strategies to prevent HAIs, which are responsible for considerable morbidity and mortality among hospitalized patients. Despite the association between resistance and increased decolonization failure, HAIs due to MRSA have dropped over the last decade despite increased mupirocin and CHG use.
Although the clinical implications of S. aureus resistance to CHG and mupirocin are unclear, the potential epidemiologic risks including CHG co-or cross-resistance to other agents and horizontal transfer of resistance genes are considerable and warrant further study. Future studies examining the efficacy of CHG and mupirocin-based decolonization must be done with longer or delayed periods of follow-up in order to determine decolonization efficacy in settings with resistance.
In order to minimize selection pressure for the development and spread of resistance to CHG and mupirocin, it is reasonable to limit the use of these valuable agents for indications without established benefit, such as mupirocin for skin infections or over-the-counter use [2] . Similarly, some have called for "antiseptic stewardship" measures restricting nonevidence based CHG applications, such as eliminating CHG from alcohol-based rubs or soaps for routine hand hygiene [30•] , which may help to control CHG resistance in the healthcare environment. Uncertainty remains whether the risks of increased resistance to these agents associated with universal decolonization (versus targeted decolonization) outweigh the possible benefits of feasibility, efficacy, and cost.
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